June 24, 2025

Fasting Triggers Inflammation, Platelet Activity, Metabolic Shift 

A human fasting study found that prolonged water-only fasting raised inflammatory and platelet activation markers, reduced amyloid beta proteins, and altered lipid and glucose metabolism, with most changes reversing after refeeding.

Conexiant

June 24, 2025

Liraglutide Linked to Fewer Migraine Days

A small observational study found that liraglutide, a GLP-1 receptor agonist typically used to treat diabetes and support weight loss, significantly reduced migraine frequency in adults with a BMI of 30 or higher—independent of weight change.

Conexiant

June 23, 2025

Central Body Fat Tied to Psoriasis Risk: Study

A large UK study of more than 336,000 adults found that central body fat, especially around the abdomen, was strongly linked to a higher risk of psoriasis, with the association more pronounced in women and independent of genetic risk.

Conexiant

June 23, 2025

Higher SCFAs in Blood Predict Diabetes Risk

New research following Spanish adults over 7 years found that higher levels of specific gut-derived fatty acids in the blood—especially butyrate and isobutyrate—were linked to an increased risk of developing type 2 diabetes, offering insights into early risk prediction.

Conexiant

June 23, 2025

IBS Relief: Which Diet Wins?

A randomized trial found that while both Mediterranean and low-FODMAP diets improved symptoms in patients with nonconstipated IBS, the low-FODMAP diet led to greater reductions in symptom severity.

Conexiant

June 18, 2025

Weight Loss Showdown: Pills or Scalpel?

A large analysis presented at the ASMBS Annual Meeting found bariatric surgery led to greater long-term weight loss than GLP-1 medications semaglutide and tirzepatide over three years.

Conexiant

June 17, 2025

Global Study Maps Sex Differences in Care

A global study found sex differences in risk factors, care access, and mortality for hypertension, diabetes, and HIV, using comprehensive international datasets.

Conexiant

June 17, 2025

Is Stroke Risk Lower with Semaglutide?

Semaglutide lowered stroke risk compared to empagliflozin in adults with type 2 diabetes, though overall mortality and heart attack rates were similar between the two drugs.

Conexiant

June 17, 2025

Does Stopping Obesity Treatment Early Undermine Success?

A large real-world study found that early discontinuation of semaglutide or tirzepatide in patients with obesity led to significantly smaller reductions in body weight and HbA1c compared to patients who continued treatment.

Conexiant